Ukrainian Journal Health of Woman. 2025. 6(181): 94-100. doi: 10.15574/HW.2025.6(186).94100
R.M. Banakhevych¹, V.A. Shamrai², N.V. Tytarenko², V.O. Rud², O.V. Bodnarchuk³, G.V. Bevz², P.P. Slobodian^2
1Dnipro State Medical University, Ukraine
²National Pirogov Memorial Medical University, Vinnytsya, Ukraine
_^3.Vinnytsia Regional Hospital named after M.I. Pirogov, Ukraine

For citation: Banakhevych RM, Shamrai VA, Tytarenko NV, Rud VO, Bodnarchuk OV, Bevz GV, Slobodian PP. (2025). Neoadjuvant combined systemic chemotherapy in the treatment of advanced epithelial ovarian cancer: clinical experience. Ukrainian Journal Health of Woman. 6(181): 94-100. doi: 10.15574/HW.2025.6(186).94100
Article received: Aug 26, 2025. Accepted for publication: Nov 20, 2025.

Ovarian cancer ranks second or third among the most common gynecologic malignancies in many countries and is associated with a high mortality rate. The main method of treating this pathology is a combination of cytoreductive surgery and systemic chemotherapy, which is administered in either the neoadjuvant or adjuvant setting depending on the specific clinical situation. In cases of tumor unresectability, carcinomatosis, or the presence of concomitant diseases, neoadjuvant chemotherapy is increasingly used, with the aim of increasing the likelihood of complete tumor resection during cytoreductive surgery. Attempts to identify subgroups of patients who are likely to benefit from neoadjuvant chemotherapy remain the subject of active scientific research.
Aim – to describe and analyze the results of combined neoadjuvant chemotherapy with aflibercept in the treatment of advanced epithelial ovarian cancer to increase doctors' awareness of this pathology.
Clinical case. A clinical case is presented involving the treatment of a 65-year-old patient with poorly differentiated serous ovarian adenocarcinoma, peritoneal dissemination, ascites, and high tumor burden (FIGO IIIC, pT3N0M0) (PCI 31). A distinctive feature of this case was the administration of six cycles of neoadjuvant combination systemic chemotherapy, which made it possible to achieve a marked partial response, followed by complete cytoreductive surgery and positive dynamics of tumor markers CA-125, HE4, and ROMA. The role of aflibercept in the treatment of epithelial ovarian carcinoma is also discussed.
Conclusions. Epithelial ovarian cancer is one of the most common pathologies in terms of incidence and mortality in modern gynecologic oncology practice. Approximately 75% of cases are diagnosed at advanced stages of the disease, when the possibility of complete resectability is debatable.
In cases of tumor unresectability and/or the inability to achieve complete cytoreduction, a promising approach is to supplement standard neoadjuvant chemotherapy with an angiogenesis inhibitor (aflibercept), which can increase the likelihood of complete resection of the neoplasm during cytoreductive surgery, accompanied by a positive trend in tumor markers.
Written informed consent for treatment and publication of this case was obtained from the patient.
No conflict of interests was declared by the authors.
Keywords: ovarian cancer, serous adenocarcinoma, neoadjuvant, chemotherapy, surgery, anti-VEGF therapy, cytoreduction, tumor markers.

REFERENCES

1. Barnard ME, Farland LV, Yan B, Wang J, Trabert B, Doherty JA et al. (2024). Endometriosis Typology and Ovarian Cancer Risk. JAMA. 332(6): 482-489. https://doi.org/10.1001/jama.2024.9210; PMid:39018030 PMCid:PMC11255975

2. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 365(26): 2473-2483. https://doi.org/10.1056/NEJMoa1104390; PMid:22204724 PMCid:PMC10111509

3. Camargo MC, Stayner LT, Straif K, Reina M, Al-Alem U et al. (2011). Occupational exposure to asbestos and ovarian cancer: a meta-analysis. Environ Health Perspect. 119(9): 1211-1217. https://doi.org/10.1289/ehp.1003283; PMid:21642044 PMCid:PMC3230399

4. Caruso G, Weroha SJ, Cliby W. (2025). Ovarian Cancer: A Review. JAMA. 334(14): 1278-1291. https://doi.org/10.1001/jama.2025.9495; PMid:40690248

5. Gaillard S, Lacchetti C, Armstrong DK, Cliby WA, Edelson MI, Garcia AA et al. (2025). Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. J Clin Oncol. 43(7): 868-891. https://doi.org/10.1200/JCO-24-02589; PMid:39841949 PMCid:PMC11934100

6. Global Cancer Observatory. (2022). Ovary fact sheet. URL: https://gco.iarc.who.int/media/globocan/factsheets/cancers/25-ovary-fact-sheet.pdf (Accessed on February 28, 2024).

7. Guan X, Wei R, Yang R, Lu Z, Liu E, Zhao Z et sl. (2021). Association of Radiotherapy for Rectal Cancer and Second Gynecological Malignant Neoplasms. JAMA Netw Open. 4(1): e2031661. https://doi.org/10.1001/jamanetworkopen.2020.31661; PMid:33416884 PMCid:PMC7794669

8. Minalt N, Caldwell A, Yedlicka GM, Joseph S, Robertson SE et al. (2023). Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review. Am J Obstet Gynecol. 229(2): 93-100. https://doi.org/10.1016/j.ajog.2023.03.039; PMid:37001577

9. Moroney JW, Sood AK, Coleman RL. (2009). Aflibercept in epithelial ovarian carcinoma. Future Oncol. 5(5): 591-600. https://doi.org/10.2217/fon.09.35; PMid:19519199 PMCid:PMC2744352

10. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G et al. (2011). A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 365(26): 2484-2496. https://doi.org/10.1056/NEJMoa1103799; PMid:22204725

11. Pierre ME, Manneh R, Hernández A, Rodríguez J, Fletcher AV, Ramírez HM et al. (2024). Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer. Rev Colomb Obstet Ginecol. 75(1): 4094. https://doi.org/10.18597/rcog.4094

12. Salani R, Bristow RE. (2012). Surgical management of epithelial ovarian cancer. Clin Obstet Gynecol. 55(1): 75-95. https://doi.org/10.1097/GRF.0b013e31824b4629; PMid:22343231

13. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. (2025). Cancer statistics, 2025. CA Cancer J Clin. 75(1): 10-45. https://doi.org/10.3322/caac.21871; PMid:39817679 PMCid:PMC11745215

14. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71(3): 209-249. https://doi.org/10.3322/caac.21660; PMid:33538338

15. Suresh B, Patel P. (2025). Aflibercept.. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. PMID: 35881741.

16. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD et al. (2018). Ovarian cancer statistics, 2018. CA Cancer J Clin. 68(4): 284-296. https://doi.org/10.3322/caac.21456; PMid:29809280 PMCid:PMC6621554

17. Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K et al. (2011) Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 105(9): 1436-1442. https://doi.org/10.1038/bjc.2011.371; PMid:21915124 PMCid:PMC3241548

18. Van Meurs HS, Tajik P, Hof MH, Vergote I, Kenter GG, Mol BW et al. (2013). Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer. 49(15): 3191-3201. https://doi.org/10.1016/j.ejca.2013.06.013; PMid:23850170

19. Weitzner O, Yagur Y, Kadan Y, Fishman A, Zissin R, Ben-Ezry E et al. (2022). Upfront surgery in patients with epithelial ovarian cancer and enlarged supradiaphragmatic lymph nodes associated with comparable to neoadjuvant chemotherapy. BMC Womens Health. 22(1): 531. https://doi.org/10.1186/s12905-022-02082-5; PMid:36529743 PMCid:PMC9762080

20. Wen H, Xu Q, Sheng X, Li H, Wang X, Wu X. (2023). Prevalence and Landscape of Pathogenic or Likely Pathogenic Germline Variants and Their Association With Somatic Phenotype in Unselected Chinese Patients With Gynecologic Cancers. JAMA Netw Open. 6(7): e2326437. https://doi.org/10.1001/jamanetworkopen.2023.26437; PMid:37523182 PMCid:PMC10391307

21. Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV et sl. (2016). Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol. 34(24): 2888-2898. https://doi.org/10.1200/JCO.2016.66.8178; PMid:27325851 PMCid:PMC5012665

22. Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG et al. (2007). Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 25(24): 3621-3627. https://doi.org/10.1200/JCO.2006.10.2517; PMid:17704411

23. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL et al. (2016). Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 34(28): 3460-3473. https://doi.org/10.1200/JCO.2016.68.6907; PMid:27502591 PMCid:PMC5512594